IMAGE: Strategy for utilizing self-healing microcapsules to modulate immunization microenvironments in cancer vaccination view more
Credit: WEI Wei
Developing safe and efficient bioformulations using approved materials and ingenious designs can accelerate the clinical translation process.
Scientists from the Institute of Process Engineering (IPE) of the Chinese Academy of Sciences have developed a new therapeutic tumor vaccine based on self-healing polylactic acid microcapsules, which can efficiently activate the immune system and inhibit tumor development.
This research was published in Science Advances on May 22.
Therapeutic cancer vaccines that harness the immune system to reject cancer cells have shown great promise for tumor treatment.
The research team, led by Prof. MA Guanghui and Prof. WEI Wei from IPE, already designed and fabricated a variety of tumor vaccines in their previous work. Theses vaccines have been proven effective in different tumor models, such as lymphoma, melanoma and breast cancer.
The researchers were impelled to improve the earlier tumor vaccines, however, due to certain limitations. For example, Prof. MA said that an unfavorable immunization microenvironment, along with a complicated preparation process and the need for frequent vaccinations significantly compromised their performance. “Therefore, we designed a novel microcapsule-based formulation for high-performance cancer vaccinations,” said
Article originally posted at